<DOC>
	<DOC>NCT00627536</DOC>
	<brief_summary>This study was undertaken to investigate the scar-improvement efficacy and safety of a single dose of avotermin (Juvista) injection into skin incisions.</brief_summary>
	<brief_title>Scar-Improvement Efficacy and Safety of a Single Intradermal Injection of Avotermin (Juvista) Administered Following Full-Thickness Skin Incisions</brief_title>
	<detailed_description />
	<mesh_term>Cicatrix</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Males and females aged 1885 years who had given written informed consent. Subjects with a body mass index within 15 to 35 kg/m2. Subjects with clinically acceptable results for the laboratory tests Female subjects of child bearing potential who are using acceptable method(s) of contraception. Subjects with history or evidence of hypertrophic or keloid scarring. Subjects with tattoos or previous scars within 3cm of the area to be incised. Subjects with prior surgery in the area to be incised within one year of the first dosing day. Subjects with a history of a bleeding disorder; receiving anticoagulant or antiplatelet therapy. Subjects with evidence of any past or present clinically significant disease that may affect the endpoints of the trial. Subjects with a clinically significant skin disorder that is chronic or currently active. Subjects with any clinically significant medical condition or history that would impair wound healing. Subjects with a history of drug hypersensitivity to any of the drugs or dressings used in this trial. Subjects who are taking, or have taken any investigational product or participated in a clinical trial in the three months prior to first trial dose administration. Subjects who are taking regular, continuous, oral corticosteroid therapy. Subjects undergoing investigations or changes in management for an existing medical condition. Subjects with a history of drug abuse, or with a positive drugs of abuse test for cocaine, amphetamines, metamphetamines, opiates or benzodiazepines during the screening period. Subjects who are considered unlikely to complete the trial for whatever reason. Subjects with a clinically significant neurological impairment or disease. Subjects with any active infection. Subjects who are pregnant or lactating.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>scarring, Juvista, avotermin, transforming growth factor beta 3, TGFB3</keyword>
</DOC>